Even though the clinical relevance with the aforementioned cardiovascular threat factor alterations by tirzepatide might be assessed in the prepared cardiovascular consequence review SURPASS-CVOT ( "variety":"scientific-trial","attrs": "text":"NCT04255433","term_id":"NCT04255433" NCT04255433), a pre-specified cardiovascular meta-analysis indicated